Full-length HIV-1 Tat protein necessary for a vaccine

Vaccine

Volumn 22, Issue 23-24, 2004, Pages 3105-3111

  Opi, Sandrine ^a   Péloponèse Jr , Jean Marie ^b   Esquieu, Didier ^a   Watkins, Jennifer ^a   Campbell, Grant ^a   De Mareuil, Jean ^a   Jeang, Kuan Teh ^b   Yirrell, David L ^c,d   Kaleebu, Pontiano ^d   Loret, Erwann P ^a  

^a CNRS   (France)

^b NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^c GARTNAVEL GENERAL HOSPITAL   (United Kingdom)

^d UGANDA VIRUS RESEARCH INSTITUTE   (Uganda)

Author keywords

Conformational epitopes; HIV vaccine; Tat

Indexed keywords

ANTIBODY; ANTISERUM; EPITOPE; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; NEUTRALIZING ANTIBODY; TRANSACTIVATOR PROTEIN;

ANIMAL EXPERIMENT; ANTIBODY TITER; ARTICLE; CARBOXY TERMINAL SEQUENCE; COMPARATIVE STUDY; CONFORMATION; CONTROLLED STUDY; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; MOLECULAR RECOGNITION; NONHUMAN; PRIORITY JOURNAL; RABBIT; SEQUENCE ANALYSIS; SEQUENCE HOMOLOGY; SERUM;

AIDS VACCINES; AMINO ACID SEQUENCE; ANIMALS; BLOTTING, WESTERN; ENZYME-LINKED IMMUNOSORBENT ASSAY; EPITOPES; GENE PRODUCTS, TAT; HIV-1; MOLECULAR SEQUENCE DATA; NEUTRALIZATION TESTS; PROTEIN CONFORMATION; RABBITS; TRANS-ACTIVATION (GENETICS);

EID: 3843104782     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2004.01.057     Document Type: Article

References (27)

1. Gallo R.C. Tat as one key to HIV-induced immune pathogenesis and Tat (correction of Pat) toxoid as an important component of a vaccine. Proc. Natl. Acad. Sci. U.S.A. 96:1999;8324-8326
2. Jeang K.T., Xiao H., Rich E.A. Multifaceted activities of the HIV-1 transactivator of transcription, Tat. J. Biol. Chem. 274:1999;28837-28840
3. Fisher A.G., Feinberg M.B., Josephs S.F., Harper M.E., Marselle L.M., Reyes G., et al. The trans-activator gene of HTLV-III is essential for virus replication. Nature. 320:1986;367-371
4. Berkhout B., Gatignol A., Rabson A.B., Jeang K.T. TAR-independent activation of the HIV-1 LTR: evidence that tat requires specific regions of the promoter. Cell. 62:1990;757-767
5. Loret E.P., Georgel P., Johnson W.C., Ho P.S. Circular dichroism and molecular modeling yield a structure for the complex of human immunodeficiency virus type 1 trans-activation response RNA and the binding region of Tat, the trans-acting transcriptional activator. Proc. Natl. Acad. Sci. U.S.A. 89:1992;9734-9738
6. Ensoli B., Gendelman R., Markham P., Fiorelli V., Colombini S., Raffeld M., et al. Synergy between basic fibroblast growth factor and HIV-1 Tat protein in induction of Kaposi's sarcoma. Nature. 371:1994;674-680
7. Zagury J.F., Sill A., Blattner W., Lachgar A., Le Buanec H., Richardson M., et al. Antibodies to the HIV-1 Tat protein correlated with nonprogression to AIDS: a rationale for the use of Tat toxoid as an HIV-1 vaccine. J. Hum. Virol. 1:1998;282-292
8. Ensoli B., Barillari G., Salahuddin S.Z., Gallo R.C., Wong-Staal F. Tat protein of HIV-1 stimulates growth of cells derived from Kaposi's sarcoma lesions of AIDS patients. Nature. 345:1990;84-86
9. Weiss J.M., Nath A., Major E.O., Berman J.W. HIV-1 Tat induces monocyte chemoattractant protein-1-mediated monocyte transmigration across a model of the human blood-brain barrier and up-regulates CCR5 expression on human monocytes. J. Immunol. 163:1999;2953-2959
10. Cohen S.S., Li C., Ding L., Cao Y., Pardee A.B., Shevach E.M., et al. Pronounced acute immunosuppression in vivo mediated by HIV Tat challenge. Proc. Natl. Acad. Sci. U.S.A. 96:1999;10842-10847
11. Alimonti J.B., Ball T.B., Fowke K.R. Mechanisms of CD4+ T lymphocyte cell death in human immunodeficiency virus infection and AIDS. J. Gen. Virol. 84:2003;1649-1661
12. Rana T.M., Jeang K.T. Biochemical and functional interactions between HIV-1 Tat protein and TAR RNA. Arch. Biochem. Biophys. 365:1999;175-185
13. Fiorelli V., Barillari G., Toschi E., Sgadari C., Monini P., Sturzl M., Ensoli B. IFN-gamma induces endothelial cells to proliferate and to invade the extracellular matrix in response to the HIV-1 Tat protein: implications for AIDS-Kaposi's sarcoma pathogenesis. J. Immunol. 162:1999;1165-1170
14. Roof P., Ricci M., Genin P., Montano M.A., Essex M., Wainberg M.A., et al. Differential regulation of HIV-1 clade-specific B, C, and E long terminal repeats by NF-kappaB and the Tat transactivator. Virology. 296:2002;77-83
15. Opi S., Peloponese J.M. Jr., Esquieu D., Campbell G., de Mareuil J., Walburger A., et al. Tat HIV-1 primary and tertiary structures critical to immune response against non-homologous variants. J. Biol. Chem. 277:2002;35915-35919
16. Addo M.M., Altfeld M., Rosenberg E.S., Eldridge R.L., Philips M.N., Habeeb K., et al. The HIV-1 regulatory proteins Tat and Rev are frequently targeted by cytotoxic T lymphocytes derived from HIV-1-infected individuals. Proc. Natl. Acad. Sci. U.S.A. 98:2001;1781-1786
17. Jeang KT. In: Los Alamos National Laboratory (Ed.), Human retrovirus and AIDS, compendium III; 1996. p. 3-18.
18. Barany G, Merrifield RB. The peptide: analysis, synthesis, biology, vol. 2. New York: Academic Press; 1980.
19. Péloponèse J.M. Jr., Collette Y., Gregoire C., Bailly C., Campese D., Meurs E.F., et al. Full peptide synthesis, purification, and characterization of six Tat variants. Differences observed between HIV-1 isolates from Africa and other continents. J Biol Chem. 274:1999;11473-11478
20. Towbin H., Staehelin T., Gordon J. Electrophoretic transfer of proteins from polyacrylamide gels to nitrocellulose sheets: procedure and some applications. Proc. Natl. Acad. Sci. U.S.A. 76:1979;4350-4354
21. McPhee D.A., Kemp B.E., Cumming S., Stapleton D., Gust I.D., Doherty R.R. Recognition of envelope and tat protein synthetic peptide analogs by HIV positive sera or plasma. FEBS Lett. 233:1988;393-396
22. Péloponèse J.M. Jr., Gregoire C., Opi S., Esquieu D., Sturgis J., Lebrun E., et al. 1H-13C nuclear magnetic resonance assignment and structural characterization of HIV-1 Tat protein. C. R. Acad. Sci. III. 323:2000;883-894
23. Gregoire C., Peloponese J.M. Jr., Esquieu D., Opi S., Campbell G., Solomiac M., et al. Homonuclear (1)H-NMR assignment and structural characterization of human immunodeficiency virus type 1 Tat Mal protein. Biopolymers. 62:2001;324-335
24. Tikhonov I., Ruckwardt T.J., Hatfield G.S., Pauza C.D. Tat-neutralizing antibodies in vaccinated macaques. J. Virol. 77:2003;3157-3166
25. Kaul R., Rowland-Jones S.L., Kimani J., Fowke K., Dong T., Kiama P., et al. New insights into HIV-1 specific cytotoxic T-lymphocyte responses in exposed, persistently seronegative Kenyan sex workers. Immunol Lett. 79:2001;3-13
26. Rowland-Jones S.L., Nixon D.F., Aldhous M.C., Gotch F., Ariyoshi K., Hallam N., et al. HIV-specific cytotoxic T-cell activity in an HIV-exposed but uninfected infant. Lancet. 341:1993;860-861
27. Novitsky V.A., Montano M.A., McLane M.F., Renjifo B., Vannberg F., Foley B.T., et al. Molecular cloning and phylogenetic analysis of human immunodeficiency virus type 1 subtype C: a set of 23 full-length clones from Botswana. J. Virol. 73:1999;4427-4432